The U.S. patent system provides an important incentive for innovation, promotes collaboration among trusted partners, and helps to advance the development of new medicines. But the Administration has a new proposal that would insert substantial uncertainty into the Bayh‐Dole framework, would undermine its policy objectives and deter collaborations that can help bring medicines to patients.
